首页> 外文期刊>In vivo. >A Case of Hydroxyurea-induced Leg Ulcer after Definitive Treatment Suspension in a Patient Affected by Thrombocythemia: Effectiveness of a New Collagenase.
【24h】

A Case of Hydroxyurea-induced Leg Ulcer after Definitive Treatment Suspension in a Patient Affected by Thrombocythemia: Effectiveness of a New Collagenase.

机译:接受血栓性红细胞增多症患者明确治疗中止后羟基尿素诱发的腿部溃疡的病例:新型胶原酶的有效性。

获取原文
获取原文并翻译 | 示例
       

摘要

Hydroxyurea (HU) is an antitumor agent effective in the treatment of myeloproliferative disorders. It is usually well-tolerated and has low toxicity but its use is associated with several adverse cutaneous effects. Among them, leg ulcers have been noted in association with long-term administration. Poor response to traditional local and systemic therapy is a typical feature of HU-induced leg ulcers, and discontinuation of the drug is often required to achieve complete wound healing. We present a case of circumferential HU-induced leg ulcer in a patient affected by essential thrombocythemia, in which the lesion occured after the definitive suspension of the treatment. We propose a conservative management with a new collagenase (Bionect Start?) for skin lesions in this type of patient, for whom a surgical treatment could be more complicated, due to the underlying disease.
机译:羟基脲(HU)是一种有效的抗肿瘤药物,可治疗骨髓增生性疾病。它通常具有良好的耐受性,并且毒性低,但其使用会引起多种不良皮肤影响。其中,长期服用已引起腿部溃疡。对传统局部和全身疗法的不良反应是HU诱发腿部溃疡的典型特征,通常需要停药以实现完全伤口愈合。我们介绍了在原发性血小板增多症患者中发生HU引起的周围性小腿溃疡的情况,该病在确定的中止治疗后发生。对于这种类型的患者,我们建议采用新的胶原酶(Bionect Start?)进行保守治疗,由于潜在疾病,对于这些患者而言,手术治疗可能会更加复杂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号